| tigilanol tiglate (EBC-46) / Qbiotics |
QB46C-H04, NCT05234437: A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma |
|
|
| Terminated | 2b | 1 | RoW | tigilanol tiglate, EBC-46 | QBiotics Group Limited | Melanoma | 07/22 | 07/22 | | |
NCT05755113: A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma |
|
|
| Recruiting | 2a | 10 | US | Tigilanol Tiglate, EBC-46 | QBiotics Group Limited | Soft Tissue Sarcoma | 07/24 | 03/25 | | |
NCT05608876: A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer |
|
|
| Recruiting | 2 | 37 | Europe, RoW | Tigilanol Tiglate, EBC-46 | QBiotics Group Limited | Head and Neck Cancer | 08/25 | 10/26 | | |
NCT04834973: A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma |
|
|
| Terminated | 1/2 | 3 | RoW | tigilanol tiglate, EBC-46, pembrolizumab, Keytruda | QBiotics Group Limited, Merck Sharp & Dohme LLC | Melanoma | 07/22 | 07/22 | | |